Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 6, 2013, Pages 1003-1006

  Rosow, David E ^a   Parikh, Punam ^a   Vivero, Richard J ^a   Casiano, Roy R ^a   Lundy, Donna S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Botox; Botulinum toxin; Dosing; Dystonia; Neurolaryngology; Spasmodic dysphonia; Voice

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN;

ADULT; ARTICLE; BREATHING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; SPASMODIC DYSPHONIA; TERTIARY HEALTH CARE; VOICE; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DOSING; DRUG ADMINISTRATION; DYSPHONIA; DYSTONIA; FOLLOW UP; INTRALESIONAL DRUG ADMINISTRATION; LARYNGOSCOPY; LARYNX MUSCLE; MIDDLE AGED; NEUROLARYNGOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BOTOX; BOTULINUM TOXIN; DOSING; DYSTONIA; NEUROLARYNGOLOGY; SPASMODIC DYSPHONIA; VOICE;

ADULT; BOTULINUM TOXINS, TYPE A; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSPHONIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; LARYNGEAL MUSCLES; LARYNGOSCOPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; TREATMENT OUTCOME; VOICE QUALITY;

MLCS; MLOWN;

EID: 84880483718     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599813484685     Document Type: Article

References (11)

1. White LJ, Hapner ER, Klein AM, et al. Coprevalence of anxiety and depression with spasmodic dysphonia: a case-control study. J Voice. 2012;26:667.
2. Ludlow CL. Spasmodic dysphonia: a laryngeal control disorder specific to speech. J Neurosci. 2011;31:793-797.
3. Brin MF, Blitzer A, Steward C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol. 1998;78:237-252.
4. Bloch CS, Hirano M, Gould WJ. Symptom improvement of spastic dysphonia in response to phonatory tasks. Ann Otol Rhinol Laryngol. 1985;94:51-54.
5. Ginsberg BI, Wallack JJ, Srain JJ, Biller HF. Defining the psychiatric role in spastic dysphonia. Gen Hosp Psychiatry. 1988; 10:132-137.
6. Dedo HH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol. 1976;85:451-459.
7. Xiao J, Zhao Y, Bastian RW, et al. Novel THAP1 sequence variants in primary dystonia. Neurology. 2010;74:229-238.
8. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of spastic dysphonia'' as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope. 1986;96:1300-1301.
9. Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2007;116:891-896.
10. Novakovic D, Waters HH, D'Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope. 2011;121:606-612.
11. Chang CY, Chabot P, Thomas JP. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2007;136: 894-899.